Prostate Cancer Treatments Enhanced
In another Varian-sponsored workshop, Constantine A. Mantz, MD, chief medical officer at 21st Century Oncology in Fort Myers, Florida, presented early results from a prospective Phase II study showing that low-risk prostate cancer patients treated with radiosurgery using Calypso® real-time tracking technology had favorable health-related quality of life scores and minimal toxicities. The study examined 84 patients who received treatment between January 2007 and January 2011. Patients received five treatments, on alternating days, each of 8.0 Gray units (a measure of radiation dose). Patients completed a quality of life questionnaire before and after treatment. Follow-up data was collected from patients 3, 6, and 9 months, as well as 1, 2 and 3 years post treatment.
Mantz pointed out that real-time tumor tracking is proving to be an important tool for reducing treatment margins during SBRT for prostate cancer, which is critical in limiting side effects.
"Based on 36 months' worth of follow up data, our prostate cancer trial is showing that real-time tumor tracking with SBRT (a form of radiosurgery targeting tumors in the body) appears to have clinically significant benefits in decreasing acute toxicity, as well as improving quality of life and biochemical outcomes," he said. "The Calypso real time tracking technology enables us to deliver increased doses of radiation accurately to the tumor and minimize exposure of surrounding healthy tissues. These are the fundamental goals when treating prostate cancer."
"Radiosurgery is poised to make a big difference in how cancer is treated," said Tim Guertin, president and CEO of Varian Medical Systems, a major co-sponsor of the meeting, in an address he made during on
|SOURCE Varian Medical Systems|
Copyright©2010 PR Newswire.
All rights reserved